Compare STK & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STK | DNA |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 616.5M | 562.3M |
| IPO Year | N/A | N/A |
| Metric | STK | DNA |
|---|---|---|
| Price | $36.31 | $8.33 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 38.2K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 6.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,606,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.95 | $5.00 |
| 52 Week High | $34.31 | $17.58 |
| Indicator | STK | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 35.56 |
| Support Level | $34.63 | $8.17 |
| Resistance Level | $38.33 | $8.90 |
| Average True Range (ATR) | 0.72 | 0.59 |
| MACD | -0.15 | -0.00 |
| Stochastic Oscillator | 45.74 | 1.01 |
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.